Beyond Air Q2 net loss $12.0M ($0.40/sh); LungFit PH launch; UNO combo data positive

Beyond Air, Inc.

2024-Q2 EPS reported -$0.77

Net loss attributable to shareholders $12.0M ($0.40 per share) for Q2 FY2023 ended Sep 30, 2022.
Cash and equivalents $72.5M as of Sep 30; cash burn $10.4M in quarter, within guidance of $8-10M.
LungFit PH commercial launch progressing; CE Mark expected end of 2022; PMA supplement for cardiac label expansion planned.
Preclinical data shows UNO + anti-PD-1 leads to higher tumor regression and prolonged survival in CT26 mice.
Beyond Cancer Phase 1 solid tumor study first patient dosed Aug 2022; topline data expected H1 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Beyond Air, Inc. reported fiscal quarter ended September 30, 2022 results: net income $12.8 million, EPS ($0.40) per share.

Period: fiscal quarter ended September 30, 2022
Net income: $12.8 million
EPS: ($0.40) per share
Result: reported results

Exact text from the filing

For the fiscal quarter ended September 30, 2022, Beyond Air, Inc. (the “Company”) had a net loss of $12.8 million, of which $12.0 million, or ($0.40) per share, was attributable to the shareholders of Beyond Air, compared with a net loss of $8.7 million, or ($0.36) per share, for the fiscal quarter ended September 30, 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Beyond Air, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-032063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.